IRVINE, Calif., Sept. 14, 2006 (PRIMEZONE) -- "Biotechnology companies know that opportunity is at the proverbial door with the aging of the massive Baby Boomer demographic,'' stated SmallCap Sentinel analyst D.R. Clark. "But fewer companies will find that they possess both the innovation and ability to capitalize in time.''
"It's not enough to simply have a better mousetrap,'' Clark added. "A company must efficiently manufacture and distribute their technology, effectively bringing it to market. This perhaps best explains the latest move by MIV Therapeutics (OTCBB:MIVT), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices. Just today they announced the acquisition of Vascore, a China-based manufacturer of advanced cardiovascular stents and other medical devices. This move should significantly accelerate MIV's commercialization of better, safer products for the multibillion-dollar vascular stent market."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Boston Scientific CP (NYSE:BSX). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/autoir/mivt_autoir.html
To have your company featured in SmallCap Sentinel please email sts@marketpathways.com or use the contact number below. Individuals may also register to receive free future reports at:
http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen thousand dollars by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a forty-five day period. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.